Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE (ARGX) is a global immunology company listed on Euronext and Nasdaq that focuses on severe autoimmune diseases through antibody-based medicines. Its news flow centers on clinical data, regulatory milestones, commercial performance and strategic updates related to its FcRn-targeting medicine VYVGART and a broader pipeline of experimental antibodies.
Investors and healthcare observers following ARGX news can read about regulatory interactions such as the U.S. Food and Drug Administration’s acceptance for priority review of a supplemental Biologics License Application (sBLA) for VYVGART in acetylcholine receptor antibody seronegative generalized myasthenia gravis (gMG). Company announcements also cover Phase 3 trial readouts, including the ADAPT SERON study in seronegative gMG and other registrational programs across neuromuscular and autoimmune indications.
argenx regularly reports preliminary and quarterly financial results, highlighting global product net sales from the VYVGART franchise and outlining strategic priorities tied to its long-term "Vision 2030". News items describe the expansion of VYVGART and VYVGART Hytrulo across gMG, chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenia (ITP) in certain regions, as well as progress with pipeline candidates such as empasiprubart and ARGX-119.
Corporate news includes leadership transitions, conference presentations at major medical and investor meetings, and updates from the company’s Immunology Innovation Program (IIP). For readers interested in ARGX stock and the evolution of its immunology franchise, this news feed provides a consolidated view of clinical, regulatory, commercial and corporate developments as disclosed in argenx press releases and related filings.
argenx SE, a global immunology company, will hold its annual general meeting of shareholders on May 10, 2022, at Hilton Amsterdam Airport Schiphol. Important agenda items include re-appointments to the Board of Directors, discussion of the 2021 Annual Accounts, and an advisory vote on the 2021 remuneration report. Shareholders are encouraged to use electronic proxy voting. The full agenda and documents related to the meeting are available on the argenx website.
argenx SE has successfully completed a global offering, closing the sale of 2,333,334 ordinary shares for gross proceeds of approximately $700 million (around €637 million). The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley. The shares are listed on the regulated market of Euronext Brussels. This offering allows argenx to advance its pipeline of antibody-based medicines aimed at severe autoimmune diseases, bolstering its commitment to improving patient lives.
argenx SE has announced a global offering of ordinary shares, including American Depository Shares (ADSs), aimed at raising approximately $700 million (about €637 million). The offering includes 1,551,044 ADSs priced at $300 each and 782,290 ordinary shares at €273.10 each. The anticipated closing date is March 28, 2022, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 350,000 shares. The offering is designed to support argenx's mission in treating severe autoimmune diseases.
argenx SE has initiated a global offering of $500 million in ordinary shares, potentially represented by American Depository Shares (ADSs). This offering includes a public offering in the U.S. and a private placement in Europe. The offering aims to close on a simultaneous basis. Additionally, underwriters may purchase up to 15% more shares. Notably, Baillie Gifford has expressed interest in acquiring up to $170 million of shares. The offering is overseen by J.P. Morgan, Morgan Stanley, Cowen, and SVB Leerink, with securities offered under a previously filed SEC registration statement.
argenx SE (Euronext & Nasdaq: ARGX) announced positive topline results from the Phase 3 ADAPT-SC study, showing that subcutaneous efgartigimod achieved noninferior total IgG reduction in generalized myasthenia gravis patients compared to intravenous administration. The study met its primary endpoint with a 66.4% IgG reduction at day 29, versus 62.2% for VYVGART. The company plans to submit a Biologics License Application (BLA) to the FDA by the end of 2022, aiming to enhance treatment options for patients and address the need for individualized care.
argenx reported a transformational year in 2021, highlighted by the FDA approval and U.S. launch of VYVGART, the first FcRn blocker for generalized myasthenia gravis. Full-year revenue soared to $497.3 million, a substantial increase from $41.2 million in 2020, primarily due to collaboration agreements. However, operating losses decreased to $348.7 million from $477.6 million the previous year. The company anticipates utilizing up to half of its cash reserves in 2022 to support the global launch of VYVGART and expand its pipeline with new indications.
February 28, 2022 – argenx (Euronext & Nasdaq: ARGX) announced its participation in the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 2:10 p.m. E.T. Management will engage in a fireside chat during the event. Interested parties can access a live webcast via the Investors section of the argenx website, with a replay available for 90 days after the presentation. argenx specializes in creating innovative therapies for severe autoimmune diseases.
argenx (Euronext & Nasdaq: ARGX) announced a conference call on March 3, 2022, at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update. The call will be accessible via the Investors section on the company's website. A replay will be available for a year after the call. argenx focuses on developing innovative treatments for severe autoimmune diseases and has commercialized the first approved neonatal Fc receptor blocker in the U.S. and Japan.
February 10, 2022 – argenx (Euronext & Nasdaq: ARGX), a global immunology company focused on severe autoimmune diseases, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 a.m. ET. A live webcast can be accessed on their Investors section of the argenx website, with a replay available for 90 days. argenx is known for developing the first approved neonatal Fc receptor blocker in the U.S. and Japan and is advancing various treatments for autoimmune diseases.
VYVGART™ (efgartigimod alfa), the first and only FcRn blocker, has received approval from Japan's Ministry of Health, Labour and Welfare for treating adults with generalized myasthenia gravis (gMG) unresponsive to standard therapies. This marks the second regulatory approval following its U.S. authorization on December 17, 2021. The approval supports argenx's global strategy to enhance access to this innovative treatment. VYVGART demonstrated significant efficacy in the Phase 3 ADAPT trial, showcasing superior response rates compared to placebo, reinforcing its potential in managing gMG.